Movers and stayers: The geography of residential mobility and CVD hospitalisations in Auckland, New Zealand.

The association between area-level disadvantage and health and social outcomes is unequivocal. However, less is known about the health impact of residential mobility, particularly at intra-urban scales. We used an encrypted National Health Index (eNHI) number to link individual-level data recorded in routine national health databases to construct a cohort of 641,532 participants aged 30+ years to investigate the association between moving and CVD hospitalisations in Auckland, New Zealand.

Stakeholder engagement for the New Zealand Atlas of Healthcare Variation: cardiovascular disease secondary prevention: VIEW-3.

Aims: As part of the Health Quality and Safety Commission's Atlas of Healthcare Variation in New Zealand, sociodemographic and regional differences in drug management for people with cardiovascular disease (CVD) were mapped. The aim of stakeholder engagement was to obtain feedback regarding interpretation, presentation and use of the Atlas data.

Methods: Feedback was obtained through surveys, one-on-one interviews and presentations at various meetings of clinicians, managers and researchers with an interest in CVD.

Construction and use of mapping techniques to describe the geographical distribution of medication dispensing for the secondary prevention of atherosclerotic CVD in New Zealand: VIEW-2.

Background: The Health Quality and Safety Commission (HQSC) is developing Atlases of Healthcare Variation in New Zealand. We were invited to create and map the sociogeographic distribution of medication dispensing patterns among people with atherosclerotic cardiovascular disease (CVD).

Methods: We developed two interactive online atlas 'templates' demonstrating geographical variations in CVD medication dispensing using InstantAtlas.

Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1).

Background: Triple therapy with anti-platelet/anti-coagulant, blood pressure (BP)-lowering, and statin medications improves outcomes in atherosclerotic cardiovascular disease (CVD). However, in practice there is often a substantial evidence-practice gap, with sub-optimal initiation and longer-term adherence. Our aim was to enumerate a contemporary national cohort of people with significant CVD and report the variation in CVD secondary prevention dispensing by demographic variables.